Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial

被引：0
|
作者：
Yuan Qu
Rui Huang
Lin Li
机构：
[1] West China Hospital of Sichuan University,Department of Nuclear Medicine
来源：
Annals of Nuclear Medicine | 2017年 / 31卷
关键词：
Thyroid neoplasms; Thyroidectomy; Iodine radioisotopes; Radiotherapy dosage;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：71 / 83
页数：12
相关论文
共 50 条
  • [41] Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
    Meier, Robert M.
    Bloch, Daniel A.
    Cotrutz, Cristian
    Beckman, Alan C.
    Henning, George T.
    Woodhouse, Shermian A.
    Williamson, Shirnett K.
    Mohideen, Najeeb
    Dombrowski, John J.
    Hong, Robert L.
    Brachman, David G.
    Linson, Patrick W.
    Kaplan, Irving D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (02): : 296 - 303
  • [42] Longitudinal regret after treatment for low- and intermediate-risk prostate cancer
    Hurwitz, Lauren M.
    Cullen, Jennifer
    Kim, Daniel J.
    Elsamanoudi, Sally
    Hudak, Jane
    Colston, Maryellen
    Travis, Judith
    Kuo, Huai-Ching
    Rice, Kevin R.
    Porter, Christopher R.
    Rosner, Inger L.
    CANCER, 2017, 123 (21) : 4252 - 4258
  • [43] Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
    Stephens, R.
    Gopaul, D.
    Panjwani, D.
    Lock, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S732 - S732
  • [44] Current focal therapies for the treatment of low- and intermediate-risk prostate cancer
    Malorgio, Antonio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 592 - 594
  • [45] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [46] Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer
    Bremer, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (02) : 192 - 193
  • [47] Evaluation of high-dose radioiodine therapy in differentiated and poorly differentiated metastatic thyroid cancer
    Enzian, M.
    Hering, A. H.
    Odparlik, A.
    Bahre, M.
    Meller, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S500 - S500
  • [48] The efficacy of low dose radioiodine therapy in differentiated thyroid cancer patients
    Yoon, S.
    Choi, B.
    Hong, S.
    Joh, C.
    Yoon, J.
    Lee, K.
    So, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S374 - S374
  • [49] Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
    Boike, Thomas P.
    Lotan, Yair
    Cho, L. Chinsoo
    Brindle, Jeffrey
    DeRose, Paul
    Xie, Xian-Jin
    Yan, Jingsheng
    Foster, Ryan
    Pistenmaa, David
    Perkins, Alida
    Cooley, Susan
    Timmerman, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2020 - 2026
  • [50] Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma
    Wang, Laura Y.
    Smith, Andrew W.
    Palmer, Frank L.
    Tuttle, R. Michael
    Mahrous, Azhar
    Nixon, Iain J.
    Patel, Snehal G.
    Ganly, Ian
    Fagin, James A.
    Boucai, Laura
    THYROID, 2015, 25 (03) : 300 - 307
12345